Last10K.com

U.S. Stem Cell, Inc. (USRM) SEC Filing 10-Q Quarterly report for the period ending Sunday, March 31, 2019

U.S. Stem Cell, Inc.

CIK: 1631282 Ticker: USRM
Document And Entity Information - shares
3 Months Ended
Mar. 31, 2019
May 07, 2019
Document and Entity Information [Abstract]  
Entity Registrant NameU.S. STEM CELL, INC. 
Trading Symbolusrm 
Document Type10-Q 
Current Fiscal Year End Date--12-31 
Entity Common Stock, Shares Outstanding 393,694,820
Amendment Flagfalse 
Entity Central Index Key0001388319 
Entity Current Reporting StatusYes 
Entity Filer CategoryNon-accelerated Filer 
Document Period End DateMar. 31, 2019 
Document Fiscal Year Focus2019 
Document Fiscal Period FocusQ1 
Entity Small Businesstrue 
Entity Emerging Growth Companyfalse 
Entity Ex Transition Periodfalse 

View differences made from one quarter to another to evaluate U.S. Stem Cell, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by U.S. Stem Cell, Inc..

Continue

Assess how U.S. Stem Cell, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

U.S. Stem Cell, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Document And Entity Information
Condensed Balance Sheets
Condensed Balance Sheets (Parentheticals)
Condensed Statement Of Stockholders' Deficit
Condensed Statements Of Cash Flows
Condensed Statements Of Operations
Accounting Policies, By Policy (Policies)
Note 1 - Significant Accounting Policies
Note 1 - Significant Accounting Policies (Details)
Note 1 - Significant Accounting Policies (Details) - Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share
Note 1 - Significant Accounting Policies (Tables)
Note 10 - Commitments And Contingencies
Note 10 - Commitments And Contingencies (Details)
Note 11 - Fair Value Measurement
Note 12 - Subsequent Events
Note 12 - Subsequent Events (Details)
Note 2 - Going Concern And Management's Liquidity Plans
Note 2 - Going Concern And Management's Liquidity Plans (Details)
Note 3 - Investments
Note 3 - Investments (Details)
Note 4 - Property And Equipment
Note 4 - Property And Equipment (Details)
Note 4 - Property And Equipment (Details) - Schedule Of Property And Equipment
Note 4 - Property And Equipment (Tables)
Note 5 - Right To Use Assets And Lease Liability
Note 5 - Right To Use Assets And Lease Liability (Details)
Note 5 - Right To Use Assets And Lease Liability (Details) - Disclosure Of Lease Expense
Note 5 - Right To Use Assets And Lease Liability (Details) - Maturity Analysis Under Lease Agreements
Note 5 - Right To Use Assets And Lease Liability (Details) - Summary Of Right To Use Assets And Lease Liability
Note 5 - Right To Use Assets And Lease Liability (Tables)
Note 6 - Accrued Expenses
Note 6 - Accrued Expenses (Details)
Note 6 - Accrued Expenses (Details) - Schedule Of Accrued Liabilities
Note 6 - Accrued Expenses (Tables)
Note 7 - Notes And Capital Lease Payable
Note 7 - Notes And Capital Lease Payable (Details)
Note 7 - Notes And Capital Lease Payable (Details) - Schedule Of Capital Leased Assets
Note 7 - Notes And Capital Lease Payable (Details) - Schedule Of Future Minimum Lease Payments For Capital Leases
Note 7 - Notes And Capital Lease Payable (Details) - Schedule Of Notes Payable
Note 7 - Notes And Capital Lease Payable (Tables)
Note 8 - Related Party Transactions
Note 8 - Related Party Transactions (Details)
Note 8 - Related Party Transactions (Details) - Schedule Of Related Party Notes Payable
Note 8 - Related Party Transactions (Tables)
Note 9 - Stockholders' Equity
Note 9 - Stockholders' Equity (Details)
Note 9 - Stockholders' Equity (Details) - Schedule Of Option Activity
Note 9 - Stockholders' Equity (Details) - Schedule Of Options Outstanding And Exercisable By Exercise Price Range
Note 9 - Stockholders' Equity (Details) - Schedule Of Warrants Activity
Note 9 - Stockholders' Equity (Details) - Schedule Of Warrants Outstanding And Exercisable By Exercise Price Range
Note 9 - Stockholders' Equity (Tables)

Material Contracts, Statements, Certifications & more

U.S. Stem Cell, Inc. provided additional information to their SEC Filing as exhibits

Ticker: USRM
CIK: 1388319
Form Type: 10-Q Quarterly Report
Accession Number: 0001185185-19-000653
Submitted to the SEC: Tue May 07 2019 4:03:40 PM EST
Accepted by the SEC: Tue May 07 2019
Period: Sunday, March 31, 2019
Industry: Commercial Physical And Biological Research

External Resources:
Stock Quote
Social Media
SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/usrm/0001185185-19-000653.htm